Member Communications

The Dose

The Dose is PAMED’s member-exclusive weekly e-newsletter, delivered to your inbox every Thursday. It’s a simple way to get a healthy dose of the hot topics in Pennsylvania medicine.

Each week, you’ll find news and analysis on topics like:

New health care laws and regulations
State licensure requirements & CME opportunities
Reimbursement and payer news, including MACRA-MIPS
Pennsylvania court cases that could impact physicians
How PAMED is advocating in the legislature on behalf of physicians – on issues like prior authorization, telemedicine, and scope of practice

Latest News Stories

Physicians Encouraged to Comment on Federal Vaccine Recommendation Framework

The Pennsylvania Medical Society (PAMED) encourages Pennsylvania physicians to participate in a new federal Request for Information (RFI) concerning vaccine recommendations and shared clinical decision-making.

Aug 25, 2026
Update to the Recommendations for Catch-Up and Early MMR Vaccination in the Context of Measles Outbreak Activity

Between April and August 21, 2026, the Pennsylvania Health Department (DOH) confirmed 379 measles cases across 28 counties in Pennsylvania.

Aug 24, 2026
New Organ and Tissue Donation Continuing Education Requirement: Learn More and Access the Course

Effective May 1, 2026, Pennsylvania licensed physicians must complete at least 2 hours of CME in organ and tissue donation and recovery process (organ donation).

Aug 20, 2026
CMS Ends Federal Funding for Sex Rejecting Procedures for Children

The Centers for Medicare & Medicaid Services (CMS) and Department of Health and Human Services (HHS) recently finalized a rule prohibiting Federal dollars from being used to fund sex-rejecting procedures on children and adolescents.

Aug 20, 2026
Increased Risk of Withdrawal Symptoms Associated with 7-hydroxymitragynine (7-OH) and Tianeptine After Federal Scheduling

The Drug Enforcement Agency (DEA) has issued two notices of intent to schedule three 7-hydroxymitragynine-related substances and tianeptine.

Aug 19, 2026
Risk of Severe Arboviral Disease in Patients Receiving B Cell-Depleting or Modulating Medications

There is a risk of severe arboviral neuroinvasive disease among patients who are receiving B cell-depleting or B cell-modulating medications, particularly anti-CD20 monoclonal antibodies (mAbs).

Aug 18, 2026

Copyright © 2025 Pennsylvania Medical Society. All rights reserved.